Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PFE Pfizer	$22.83 +1.0%	$23.65	$20.92 ▼ $31.54	$129.77B	0.58	40.87 million shs	37.73 million shs
SNY Sanofi	$51.68 +1.6%	$53.36	$45.80 ▼ $60.12	$130.56B	0.55	2.37 million shs	2.72 million shs
UCBJF UCB	$168.65 -1.2%	$166.91	$149.85 ▼ $209.66	$31.88B	0.47	617 shs	8 shs
VRTX Vertex Pharmaceuticals	$438.65 +1.0%	$482.97	$377.85 ▼ $519.88	$112.64B	0.51	1.41 million shs	1.51 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PFE Pfizer	+2.54%	-1.73%	+0.56%	-11.47%	-21.67%
SNY Sanofi	+3.35%	-2.44%	+0.51%	-6.68%	+3.77%
UCBJF UCB	0.00%	+13.30%	+13.30%	-10.13%	+29.36%
VRTX Vertex Pharmaceuticals	+3.14%	+1.11%	-13.21%	-5.36%	-0.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PFE Pfizer	4.9956 of 5 stars	4.3	3.0	4.2	4.3	3.3	1.7	3.1
SNY Sanofi	3.9394 of 5 stars	2.6	4.0	2.5	0.0	3.9	0.0	3.1
UCBJF UCB	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	4.4461 of 5 stars	3.3	4.0	0.0	3.3	2.9	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PFE Pfizer	2.53	Moderate Buy	$29.17	27.78% Upside
SNY Sanofi	3.14	Buy	$63.33	22.55% Upside
UCBJF UCB	0.00	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	2.59	Moderate Buy	$515.04	17.42% Upside

Current Analyst Ratings Breakdown

Latest UCBJF, PFE, SNY, and VRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/7/2025	VRTX Vertex Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/6/2025	VRTX Vertex Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/6/2025	VRTX Vertex Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/6/2025	VRTX Vertex Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/6/2025	VRTX Vertex Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$450.00 ➝ $442.00
5/6/2025	VRTX Vertex Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$420.00 ➝ $423.00
5/6/2025	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$462.00 ➝ $464.00
5/6/2025	VRTX Vertex Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$512.00 ➝ $515.00
5/6/2025	VRTX Vertex Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$535.00 ➝ $535.00
5/6/2025	VRTX Vertex Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$550.00 ➝ $503.00
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00

(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PFE Pfizer	$62.46B	2.08	$3.58 per share	6.38	$15.81 per share	1.44
SNY Sanofi	$45.17B	2.89	$5.09 per share	10.16	$33.20 per share	1.56
UCBJF UCB	$5.27B	6.05	$7.24 per share	23.28	$50.52 per share	3.34
VRTX Vertex Pharmaceuticals	$11.10B	10.15	N/A	N/A	$63.90 per share	6.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PFE Pfizer	$8.03B	$1.38	16.19	7.53	0.64	12.62%	19.47%	8.09%	7/29/2025 (Estimated)
SNY Sanofi	$6.02B	$2.80	20.76	10.88	1.01	12.77%	25.61%	14.72%	7/24/2025 (Estimated)
UCBJF UCB	$371.23M	N/A	0.00	23.89	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$3.92	N/A	25.05	2.11	-4.86%	-2.02%	-1.49%	N/A

Latest UCBJF, PFE, SNY, and VRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	VRTX Vertex Pharmaceuticals	$4.29	$4.06	-$0.23	$2.49	$2.85 billion	$2.77 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	SNY Sanofi	$0.90	$0.94	+$0.04	$0.80	$9.79 billion	$10.41 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PFE Pfizer	$1.72	7.54%	+2.50%	124.64%	16 Years
SNY Sanofi	$1.60	3.10%	+1.84%	57.14%	N/A
UCBJF UCB	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest UCBJF, PFE, SNY, and VRTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
4/15/2025	SNY Sanofi	annual	$2.0369	3.1%	5/9/2025	5/9/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PFE Pfizer	0.63	1.00	0.73
SNY Sanofi	0.15	1.46	1.14
UCBJF UCB	0.33	1.19	0.78
VRTX Vertex Pharmaceuticals	0.01	2.69	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PFE Pfizer	68.36%
SNY Sanofi	14.04%
UCBJF UCB	N/A
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
PFE Pfizer	0.06%
SNY Sanofi	1.00%
UCBJF UCB	N/A
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PFE Pfizer	83,000	5.69 billion	5.66 billion	Optionable
SNY Sanofi	91,600	2.53 billion	2.51 billion	Optionable
UCBJF UCB	9,083	189.02 million	N/A	Not Optionable
VRTX Vertex Pharmaceuticals	4,800	256.80 million	256.28 million	Optionable

UCBJF, PFE, SNY, and VRTX Headlines

Recent News About These Companies

3,802 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by Mufg Securities Americas Inc.

May 16 at 8:11 AM | marketbeat.com

Malaga Cove Capital LLC Buys Shares of 1,989 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 16 at 7:52 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Nia Impact Advisors LLC

May 16 at 7:35 AM | marketbeat.com

Nissay Asset Management Corp Japan ADV Increases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 16 at 7:35 AM | marketbeat.com

1 Large-Cap Stock to Target This Week and 2 to Question

May 16 at 6:29 AM | finance.yahoo.com

OMERS ADMINISTRATION Corp Sells 1,213 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 16 at 6:26 AM | marketbeat.com

Vertex to Participate in Upcoming Investor Conferences

May 15 at 4:05 PM | businesswire.com

Morse Asset Management Inc Has $4.25 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 15 at 6:57 AM | marketbeat.com

Jefferies Financial Group Inc. Sells 18,659 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 15 at 5:26 AM | marketbeat.com

Hudson Bay Capital Management LP Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 15 at 5:25 AM | marketbeat.com

Lazard Asset Management LLC Purchases 518,132 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 14 at 7:21 AM | marketbeat.com

Gotham Asset Management LLC Has $12.13 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 14 at 5:39 AM | marketbeat.com

Investment Management Corp of Ontario Has $6.97 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 13 at 8:23 AM | marketbeat.com

Best Biotech Stocks to Buy in 2025 (VRTX)

May 13 at 8:10 AM | marketbeat.com

Janus Henderson Group PLC Grows Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 13 at 7:56 AM | marketbeat.com

Geller Advisors LLC Cuts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 13 at 7:25 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Focus Partners Wealth

May 13 at 6:54 AM | marketbeat.com

This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Next

May 13 at 6:00 AM | fool.com

CoreCap Advisors LLC Sells 6,622 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 13 at 5:45 AM | marketbeat.com

Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years

May 12, 2025 | msn.com

Vertex Pharmaceuticals: Strong Growth and Promising Pipeline Justify Buy Rating

May 12, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UCBJF, PFE, SNY, and VRTX Company Descriptions

Pfizer NYSE:PFE

$22.82 +0.23 (+1.00%)

Closing price 03:59 PM Eastern

Extended Trading

$22.68 -0.14 (-0.63%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sanofi NASDAQ:SNY

$51.68 +0.82 (+1.61%)

Closing price 04:00 PM Eastern

Extended Trading

$51.21 -0.47 (-0.91%)

As of 06:42 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

UCB OTCMKTS:UCBJF

$168.65 -2.10 (-1.23%)

As of 10:27 AM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Vertex Pharmaceuticals NASDAQ:VRTX

$438.65 +4.27 (+0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$434.26 -4.38 (-1.00%)

As of 07:56 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time